Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO)

39 filings reported holding XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q4 2024.
Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) has 34 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 25.8M shares of 55.6M outstanding shares and own 46.47% of the company stock.
Largest 10 shareholders include GILEAD SCIENCES, INC. (9.11M shares), Bain Capital Life Sciences Investors, LLC (4.57M shares), Rock Springs Capital Management LP (3M shares), Merck & Co., Inc. (1.48M shares), TAKEDA PHARMACEUTICAL CO LTD (1.48M shares), FMR LLC (1.4M shares), MORGAN STANLEY (1M shares), VANGUARD GROUP INC (903K shares), AJU IB Investment Co., Ltd. (668K shares), and GEODE CAPITAL MANAGEMENT, LLC (358K shares).
This table shows the top 34 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.